Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma
暂无分享，去创建一个
E. Borsi | E. Zamagni | N. Testoni | M. Cavo | C. Terragna | P. Tacchetti | M. Martello | G. Marzocchi | L. Pantani | S. Rocchi | K. Mancuso | I. Rizzello | L. Dozza | Isola Caratozzolo | Alessio Fusco | G. De Cicco
[1] G. Morgan,et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.
[2] M. Kersten,et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial , 2018, Leukemia.
[3] G. Morgan,et al. Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial , 2017 .
[4] Sin-Ho Jung,et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] K. Sullivan,et al. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] D. Hose,et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. , 2012, Blood.